Summary
Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in 20 % of the cases. In case of metastatic or locally advanced, unresectable disease, standard treatments, like anthracycline-based regimens, are poorly effective. Previous studies suggested that antiangiogenic drugs, such as sorafenib, could be efficient to treat vascular sarcomas and solitary fibrous tumors. Five patients with progressive SFT were included in this phase 2 study, and treated with sorafenib at a dose of 800 mg daily. Two patients out of the five achieved a 9 months disease control with sorafenib, while their disease had progressed within the month preceding their inclusion. Consequently, our data suggest a potential efficacy of sorafenib in SFT, Further investigation is needed to confirm these data.
This is a preview of subscription content, log in via an institution to check access.
References
Penel N, Amela EY, Decanter G, Robin YM, Marec-Berard P (2012) Solitary fibrous tumors and so-called hemangiopericytoma. Sarcoma 2012:690251. doi:10.1155/2012/690251
Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM (2013) The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3(1):7. doi:10.1186/2045-3329-3-7
Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG (2012) Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 23(12):3171–3179. doi:10.1093/annonc/mds143
Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117(21):4939–4947. doi:10.1002/cncr.26098
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118(3):770–776. doi:10.1002/cncr26334
George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri JD, Keohan ML (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27(19):3154–3160. doi:10.1200/JCO.2008.20.9890
Funding
This work was supported by Institut National du Cancer (PHRC-2009/grant) and Bayer HealthCare France
Ethical and regulatory considerations
Study investigations were conducted after approval by the regional Ethics Committee (“Comité de Protection des Patients Nord-Ouest III”, date of approval: 16 June 2009) and after declaration to the French Health Products Safety Agency (“Agence Française de Sécurité Sanitaire et des Produits de Santé”, date of approval: 1 June 2009). Informed consent was obtained from each patient. This study was registered in the European Clinical Trials Register (EudraCT N° 2007-004651-10). This study had been registered in the ClinicalTrial.gov site (Number: NCT 00874874). The study was conducted in agreement with the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice guidelines.
(http://www.cancer.gov/clinicaltrials/search/view?cdrid=633547&version=healthprofessional).
Conflict of interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valentin, T., Fournier, C., Penel, N. et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs 31, 1626–1627 (2013). https://doi.org/10.1007/s10637-013-0023-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-013-0023-z